Portfolio News

Istanbul, Denizli and Izmir, Türkiye, 03 August 2025 – MicroPort® CardioFlow recently announced the first commercial implantations of its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Türkiye. 

Five procedures were performed at Kocaeli University Hospital and Pamukkale University Hospital, led by Prof. Dr. Teoman Kilic, Director of Structural Heart Interventions at Kocaeli University and President of Turkish Working Group of Interventional Cardiology, in  collaboration with Prof. Jianan Wang, Academician of the Chinese Academy of Sciences, and Prof. Xianbao Liu, Vice President of Zhejiang University School of Medicine.

All cases were successfully completed, with postoperative assessments confirmed device performance. Physicians highlighted the system’s precision, retrievability, and single-operator design, which streamlined workflow and improved efficiency. 

VitaFlow Liberty® builds on the original VitaFlow® design, featuring a hybrid-density self-expanding stent, bovine pericardial leaflets, and a dual-layer PET skirt to enhance radial strength, coaxial deployment, and sealing. Its next-generation delivery system introduces a double-helix structure that ensures accurate deployment, retrievability, and 360-degree articulation at the valve segment.

These first-in-country cases demonstrate MicroPort® CardioFlow’s commitment to delivering advanced transcatheter valve technologies with the support of world-class clinical guidance, ensuring optimal outcomes for both physicians and patients.